Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Нестероидная противовоспалительная терапия и стратегии лечения мигрени
Нестероидная противовоспалительная терапия и стратегии лечения мигрени
Шагбазян А.Э., Евдокимова Е.М., Гассиева Д.М., Табеева Г.Р. Нестероидная противовоспалительная терапия и стратегии лечения мигрени. Consilium Medicum. Неврология и Ревматология (Прил.). 2016; 2: 5–10.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Мигрень – хроническое заболевание нервной системы, которое проявляется эпизодическими приступами интенсивной головной боли. Лечение мигрени предполагает различные стратегии, включающие купирование приступов и профилактическое лечение. Несмотря на широкий арсенал средств, лечение мигрени остается трудной задачей. Учитывая сходную эффективность препаратов 1-й линии для купирования головной боли – триптанов и нестероидных противовоспалительных препаратов – выбор конкретного средства должен основываться на стратификации и общих принципах симптоматической терапии.
Ключевые слова: мигрень, нестероидные противовоспалительные препараты.
Key words: migraine, nonsteroidal antiinflammatory drugs.
Ключевые слова: мигрень, нестероидные противовоспалительные препараты.
________________________________________________
Key words: migraine, nonsteroidal antiinflammatory drugs.
Полный текст
Список литературы
1. Стайнер Т.Дж. и др. Европейские принципы ведения пациентов с наиболее распространенными формами головной боли в общей практике. Пер. с англ. Ю.Э.Азимовой, В.В. Осиповой. М., 2010; с. 56. / Stainer T.Dzh. i dr. Evropeiskie printsipy vedeniia patsientov s naibolee rasprostranennymi formami golovnoi boli v obshchei praktike. Per. s angl. Iu.E.Azimovoi, V.V. Osipovoi. M., 2010; s. 56. [in Russian]
2. Г.Р. Табеева. Головная боль: руководство для врачей. М.: ГЭОТАР-Медиа, 2014. / G.R. Tabeeva. Golovnaia bol': rukovodstvo dlia vrachei. M.: GEOTAR-Media, 2014. [in Russian]
3. Spierings EL, Ranke AH, Honkoop PC. Precipitating and aggravationg factors of migraine versus tension-type headache. Headache 2001; 41: 554–8.
4. Headache Classification Committee of the International Headache Society The International Classification of Headache Disorders. 3rd ed (beta version). Cephalalgia 2013; 33 (9): 629–808.
5. Алексеев В.В., Подчуфарова Е.В., Черненко О.А. Хроническая ежедневная головная боль. Неврологический журнал. 2001; 6: 31–7. / Alekseev V.V., Podchufarova E.V., Chernenko O.A. Khronicheskaia ezhednevnaia golovnaia bol'. Nevrologicheskii zhurnal. 2001; 6: 31–7. [in Russian]
6. Садоха К.А. Диагностика и лечение мигрени. ARS MEDICA. 2009; 3 (13): 30–40. / Sadokha K.A. Diagnostika i lechenie migreni. ARS MEDICA. 2009; 3 (13): 30–40. [in Russian]
7. Табеева Г.Р. Что такое мигрень? М., 2010; с. 92. / Tabeeva G.R. Chto takoe migren'? M., 2010; s. 92 [in Russian]
8. Cooke LJ, Becker WJ. Migraine prevalence, treatment and impact: the canadian women and migraine study. Can J Neurol Sci 2010; 37 (5): 580Y58.
9. Vos T, Flaxman AD, NaghaviM et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990Y2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380 (9859): 2163Y2196.
10. Lipton RB, StewartWF, Stone AM et al. Disability in Strategies of Care Study group. Stratified care vs step care strategies for migraine: the Disability in Strategies of Care (DISC) Study: a randomized trial. JAMA 2000; 284 (20): 2599Y2605.
11. Екушева Е.В. Оптимальные подходы к купированию приступа мигрени: прошлое, настоящее и будущее. РМЖ. 2012; 10: 522–6. / Ekusheva E.V. Optimal'nye podkhody k kupirovaniiu pristupa migreni: proshloe, nastoiashchee i budushchee. RMZh. 2012; 10: 522–6. [in Russian]
12. Азимова Ю.Э., Осипова В.В.. Лечение приступа мигрени: новые возможности и перспективы. РМЖ. 2011; 19 (15): 954–5. / Azimova Iu.E., Osipova V.V.. Lechenie pristupa migreni: novye vozmozhnosti i perspektivy. RMZh. 2011; 19 (15): 954–5. [in Russian]
13. LanteriMinet M. What do patients want from their acute migraine therapy? Eur Neurol 2005; 53 (Suppl. 1): 3–9.
14. Foley KA, Cady RK, Martin V et al. Treating early versus treating mild: timing of migraine prescription medications among patients with diagnosed migraine. Headache 2005; 45: 538–45.
15. Silberstein SD, Stirpe JC. COX inhibitors for the treatment of migraine. Expert Opin Pharmacother 2014; 15 (13); 1863–74.
16. Sternierio Е, Bussone G, Manzoni GC et al. Lornoxicam, a new non-steroidal anti-iflammatory drug, in migraine prophylaxis: a double-blind multicenter study. Cephalalgia 1991; 11 (Suppl. 11): 154–5.
17. Yener G, Uner M., Gonullu U et al. Design of Meloxicam and Lornoxicam Transdermal Patches: Preparation, Physical Characterization, ex Vivo and in Vivo Studies. Chem Pharm Bull 2010; 58 (11): 1466–73.
18. Hamza Yel-S, Aburahma MH. Design and in vitro Evaluation of novel sustained-release double-layer tablets of Lornoxicam: Utility of cyclodextrin and xanthan gum combination. AAPS Pharm Sci Tech 2009; 10: 1357–66.
2. G.R. Tabeeva. Golovnaia bol': rukovodstvo dlia vrachei. M.: GEOTAR-Media, 2014. [in Russian]
3. Spierings EL, Ranke AH, Honkoop PC. Precipitating and aggravationg factors of migraine versus tension-type headache. Headache 2001; 41: 554–8.
4. Headache Classification Committee of the International Headache Society The International Classification of Headache Disorders. 3rd ed (beta version). Cephalalgia 2013; 33 (9): 629–808.
5. Alekseev V.V., Podchufarova E.V., Chernenko O.A. Khronicheskaia ezhednevnaia golovnaia bol'. Nevrologicheskii zhurnal. 2001; 6: 31–7. [in Russian]
6. Sadokha K.A. Diagnostika i lechenie migreni. ARS MEDICA. 2009; 3 (13): 30–40. [in Russian]
7. Tabeeva G.R. Chto takoe migren'? M., 2010; s. 92 [in Russian]
8. Cooke LJ, Becker WJ. Migraine prevalence, treatment and impact: the canadian women and migraine study. Can J Neurol Sci 2010; 37 (5): 580Y58.
9. Vos T, Flaxman AD, NaghaviM et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990Y2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380 (9859): 2163Y2196.
10. Lipton RB, StewartWF, Stone AM et al. Disability in Strategies of Care Study group. Stratified care vs step care strategies for migraine: the Disability in Strategies of Care (DISC) Study: a randomized trial. JAMA 2000; 284 (20): 2599Y2605.
11. Ekusheva E.V. Optimal'nye podkhody k kupirovaniiu pristupa migreni: proshloe, nastoiashchee i budushchee. RMZh. 2012; 10: 522–6. [in Russian]
12. Azimova Iu.E., Osipova V.V.. Lechenie pristupa migreni: novye vozmozhnosti i perspektivy. RMZh. 2011; 19 (15): 954–5. [in Russian]
13. LanteriMinet M. What do patients want from their acute migraine therapy? Eur Neurol 2005; 53 (Suppl. 1): 3–9.
14. Foley KA, Cady RK, Martin V et al. Treating early versus treating mild: timing of migraine prescription medications among patients with diagnosed migraine. Headache 2005; 45: 538–45.
15. Silberstein SD, Stirpe JC. COX inhibitors for the treatment of migraine. Expert Opin Pharmacother 2014; 15 (13); 1863–74.
16. Sternierio Е, Bussone G, Manzoni GC et al. Lornoxicam, a new non-steroidal anti-iflammatory drug, in migraine prophylaxis: a double-blind multicenter study. Cephalalgia 1991; 11 (Suppl. 11): 154–5.
17. Yener G, Uner M., Gonullu U et al. Design of Meloxicam and Lornoxicam Transdermal Patches: Preparation, Physical Characterization, ex Vivo and in Vivo Studies. Chem Pharm Bull 2010; 58 (11): 1466–73.
18. Hamza Yel-S, Aburahma MH. Design and in vitro Evaluation of novel sustained-release double-layer tablets of Lornoxicam: Utility of cyclodextrin and xanthan gum combination. AAPS Pharm Sci Tech 2009; 10: 1357–66.
2. Г.Р. Табеева. Головная боль: руководство для врачей. М.: ГЭОТАР-Медиа, 2014. / G.R. Tabeeva. Golovnaia bol': rukovodstvo dlia vrachei. M.: GEOTAR-Media, 2014. [in Russian]
3. Spierings EL, Ranke AH, Honkoop PC. Precipitating and aggravationg factors of migraine versus tension-type headache. Headache 2001; 41: 554–8.
4. Headache Classification Committee of the International Headache Society The International Classification of Headache Disorders. 3rd ed (beta version). Cephalalgia 2013; 33 (9): 629–808.
5. Алексеев В.В., Подчуфарова Е.В., Черненко О.А. Хроническая ежедневная головная боль. Неврологический журнал. 2001; 6: 31–7. / Alekseev V.V., Podchufarova E.V., Chernenko O.A. Khronicheskaia ezhednevnaia golovnaia bol'. Nevrologicheskii zhurnal. 2001; 6: 31–7. [in Russian]
6. Садоха К.А. Диагностика и лечение мигрени. ARS MEDICA. 2009; 3 (13): 30–40. / Sadokha K.A. Diagnostika i lechenie migreni. ARS MEDICA. 2009; 3 (13): 30–40. [in Russian]
7. Табеева Г.Р. Что такое мигрень? М., 2010; с. 92. / Tabeeva G.R. Chto takoe migren'? M., 2010; s. 92 [in Russian]
8. Cooke LJ, Becker WJ. Migraine prevalence, treatment and impact: the canadian women and migraine study. Can J Neurol Sci 2010; 37 (5): 580Y58.
9. Vos T, Flaxman AD, NaghaviM et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990Y2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380 (9859): 2163Y2196.
10. Lipton RB, StewartWF, Stone AM et al. Disability in Strategies of Care Study group. Stratified care vs step care strategies for migraine: the Disability in Strategies of Care (DISC) Study: a randomized trial. JAMA 2000; 284 (20): 2599Y2605.
11. Екушева Е.В. Оптимальные подходы к купированию приступа мигрени: прошлое, настоящее и будущее. РМЖ. 2012; 10: 522–6. / Ekusheva E.V. Optimal'nye podkhody k kupirovaniiu pristupa migreni: proshloe, nastoiashchee i budushchee. RMZh. 2012; 10: 522–6. [in Russian]
12. Азимова Ю.Э., Осипова В.В.. Лечение приступа мигрени: новые возможности и перспективы. РМЖ. 2011; 19 (15): 954–5. / Azimova Iu.E., Osipova V.V.. Lechenie pristupa migreni: novye vozmozhnosti i perspektivy. RMZh. 2011; 19 (15): 954–5. [in Russian]
13. LanteriMinet M. What do patients want from their acute migraine therapy? Eur Neurol 2005; 53 (Suppl. 1): 3–9.
14. Foley KA, Cady RK, Martin V et al. Treating early versus treating mild: timing of migraine prescription medications among patients with diagnosed migraine. Headache 2005; 45: 538–45.
15. Silberstein SD, Stirpe JC. COX inhibitors for the treatment of migraine. Expert Opin Pharmacother 2014; 15 (13); 1863–74.
16. Sternierio Е, Bussone G, Manzoni GC et al. Lornoxicam, a new non-steroidal anti-iflammatory drug, in migraine prophylaxis: a double-blind multicenter study. Cephalalgia 1991; 11 (Suppl. 11): 154–5.
17. Yener G, Uner M., Gonullu U et al. Design of Meloxicam and Lornoxicam Transdermal Patches: Preparation, Physical Characterization, ex Vivo and in Vivo Studies. Chem Pharm Bull 2010; 58 (11): 1466–73.
18. Hamza Yel-S, Aburahma MH. Design and in vitro Evaluation of novel sustained-release double-layer tablets of Lornoxicam: Utility of cyclodextrin and xanthan gum combination. AAPS Pharm Sci Tech 2009; 10: 1357–66.
________________________________________________
2. G.R. Tabeeva. Golovnaia bol': rukovodstvo dlia vrachei. M.: GEOTAR-Media, 2014. [in Russian]
3. Spierings EL, Ranke AH, Honkoop PC. Precipitating and aggravationg factors of migraine versus tension-type headache. Headache 2001; 41: 554–8.
4. Headache Classification Committee of the International Headache Society The International Classification of Headache Disorders. 3rd ed (beta version). Cephalalgia 2013; 33 (9): 629–808.
5. Alekseev V.V., Podchufarova E.V., Chernenko O.A. Khronicheskaia ezhednevnaia golovnaia bol'. Nevrologicheskii zhurnal. 2001; 6: 31–7. [in Russian]
6. Sadokha K.A. Diagnostika i lechenie migreni. ARS MEDICA. 2009; 3 (13): 30–40. [in Russian]
7. Tabeeva G.R. Chto takoe migren'? M., 2010; s. 92 [in Russian]
8. Cooke LJ, Becker WJ. Migraine prevalence, treatment and impact: the canadian women and migraine study. Can J Neurol Sci 2010; 37 (5): 580Y58.
9. Vos T, Flaxman AD, NaghaviM et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990Y2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380 (9859): 2163Y2196.
10. Lipton RB, StewartWF, Stone AM et al. Disability in Strategies of Care Study group. Stratified care vs step care strategies for migraine: the Disability in Strategies of Care (DISC) Study: a randomized trial. JAMA 2000; 284 (20): 2599Y2605.
11. Ekusheva E.V. Optimal'nye podkhody k kupirovaniiu pristupa migreni: proshloe, nastoiashchee i budushchee. RMZh. 2012; 10: 522–6. [in Russian]
12. Azimova Iu.E., Osipova V.V.. Lechenie pristupa migreni: novye vozmozhnosti i perspektivy. RMZh. 2011; 19 (15): 954–5. [in Russian]
13. LanteriMinet M. What do patients want from their acute migraine therapy? Eur Neurol 2005; 53 (Suppl. 1): 3–9.
14. Foley KA, Cady RK, Martin V et al. Treating early versus treating mild: timing of migraine prescription medications among patients with diagnosed migraine. Headache 2005; 45: 538–45.
15. Silberstein SD, Stirpe JC. COX inhibitors for the treatment of migraine. Expert Opin Pharmacother 2014; 15 (13); 1863–74.
16. Sternierio Е, Bussone G, Manzoni GC et al. Lornoxicam, a new non-steroidal anti-iflammatory drug, in migraine prophylaxis: a double-blind multicenter study. Cephalalgia 1991; 11 (Suppl. 11): 154–5.
17. Yener G, Uner M., Gonullu U et al. Design of Meloxicam and Lornoxicam Transdermal Patches: Preparation, Physical Characterization, ex Vivo and in Vivo Studies. Chem Pharm Bull 2010; 58 (11): 1466–73.
18. Hamza Yel-S, Aburahma MH. Design and in vitro Evaluation of novel sustained-release double-layer tablets of Lornoxicam: Utility of cyclodextrin and xanthan gum combination. AAPS Pharm Sci Tech 2009; 10: 1357–66.
Авторы
А.Э.Шагбазян, Е.М.Евдокимова, Д.М.Гассиева, Г.Р.Табеева*
ФГБОУ ВО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 1
*grtabeeva@gmail.com
I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaia d. 8, str. 1
*grtabeeva@gmail.com
ФГБОУ ВО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 1
*grtabeeva@gmail.com
________________________________________________
I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaia d. 8, str. 1
*grtabeeva@gmail.com
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.